1 option
CADTH Canadian Drug Expert Committee recommendation : indication: treatment of HIV type 1 (HIV-1) infection. Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza -- Janssen Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- HIV infections--Prevention.
- HIV infections.
- Cost effectiveness.
- Physical Description:
- 1 online resource (5 pages)
- Edition:
- First edition.
- Place of Publication:
- Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2018.
- Summary:
- The CADTH Canadian Drug Expert Committee recommends that darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) be reimbursed as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with no known mutations associated with resistance to the individual components of D/C/F/TAF, if the following condition is met: condition: the total cost of treatment with D/C/F/TAF should not exceed the total drug-plan cost of treatment with the least costly alternative triple or quadruple single-tablet regimen.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.